Impact of a Novel Immune Modulating Dietary Supplement on House Dust Mite Induced Allergic Rhinoconjunctivitis

Inclusion Criteria: * Allergy to house dust mite (HDM) with rhinoconjunctivitis symptoms with/without asthma. These allergic symptoms must have been present for at least 2 years and severity assessed by anamnesis according to ARIA guidelines (mild; moderate/severe - Bousquet et al, 2007) * Positive skin test to HDM extract using a skin testing diagnostic product used in the daily routines of the clinics, with a wheal diameter \> 3 mm * Positive nasal provocation test to HDM allergen as used in the chamber and/or a history of TNSS ≥ 3 after 120 min HDM exposure in the chamber * Oral and written informed consent Exclusion Criteria: * Current or previous treatment with allergy vaccination within the last two years. * Concomitant (or newly developing during study period) severe disease interfering with allergy testing * Co-medication interfering with allergy testing for other diseases, e.g. immunosuppressants, oral and/or nasal corticosteroids, chromones and pregnancy * Clinically relevant co-sensitization to early blossoming tree pollen allergens, and cat allergens * Patient with FEV1 \< 80% of predicted value prior to exposure * Patients with severe asthma and / or with a history of uncontrolled asthmatic attacks in the last three months before the selection process * Patients with an upper intestinal tract disease, where the local examiner believes that taking the dietary supplement could pose a risk to the patient * History of serious chronic medical conditions and/or any …